//
// file taut_enum_protonate_vb.H
// David Cosgrove
// AstraZeneca
// 24th December 2013
//
// Vector bindings for the protonation SMIRKS.

#ifndef TAUT_ENUM_PROTONATE_VB
#define TAUT_ENUM_PROTONATE_VB

#include <string>

namespace DACLIB {

static const std::string SET_PROT_VB = "\n\
########################################################################\n\
# made into SMIRKS by Dave Cosgrove December 2013\n\
########################################################################\n\
# \n\
# set_prot.vb_v1.2                                    PW Kenny 15-Aug-2005\n\
#\n\
#  SBDE Ionisation and tautomer (both steps) vector bindings: Version 1.2\n\
#\n\
#  These SMARTS were generated by making set_prot.smt_v1.1\n\
#  SMARTS compatible with both Daylight and OEChem which differ in \n\
#  their use of the R and r descriptors.  \n\
#\n\
########################################################################\n\
#\n\
#  Redefine r & R descriptors to make compatible with OEChem & Daylight \n\
r3      *1~*~*1\n\
r4      *1~*~*~*1\n\
r5      *1~*~*~*~*1\n\
r6      *1~*~*~*~*~*1\n\
r7      *1~*~*~*~*~*~*1\n\
r8      *1~*~*~*~*~*~*~*1\n\
R       *(~;@*)~;@*\n\
R2      *(~;@*)(~;@*)~;@*\n\
RSpiro  A(~;@*)(~;@*)(~;@*)~;@*\n\
R1      [$R;!$R2;!$RSpiro]\n\
#\n\
#########################################################################\n\
#\n\
# Some general purpose atom types \n\
#\n\
# Amino, alkylamino & selected imino groups for \n\
# specifying guanidines, amidines & heteroaromatic\n\
# nitrogen\n\
nh2           [N;H2;X3;!+]\n\
nhr           [N;H;X3;!+][CX4]\n\
nhph          [N;H;X3;!+]c1ccccc1\n\
nr2           [N;X3;!+]([CX4])[CX4]\n\
nrph          [N;X3;!+]([CX4])c1ccccc1\n\
am            [$nh2,$nhr,$nr2]\n\
nh            [N;X2;H;!+]\n\
nr            [N;X2;!+][CX4]\n\
nph           [N;X2;!+]c1ccccc1\n\
im            [$nh,$nr]\n\
#\n\
#  Electron withdrawing group for defining carbon acids and\n\
#  identifying likely protonation state of heteroaromatic bases\n\
#\n\
CF3           C(F)(F)F\n\
EW1           [$([C,S](=O)[C,c,N,O&D2]),$(C#N)]\n\
EW2           [$(S(=O)(=O)[c,C]),$(N(=O)=O)]\n\
EW3           [$EW1,$EW2,$([F,Cl,Br]),$CF3] \n\
#\n\
# Aromatic atom types\n\
cam           c[$am]\n\
c1            [$([cH]),$(c[C;X4;!$CF3])]\n\
c2            c1ccccc1\n\
c3            [c;!$(c=A)]\n\
c4            [c;!$([c;$R2](a)(a)a)]\n\
c5            [$cam,$c1]\n\
c6            [$c5,$c2]\n\
c7            [$c1,$c2,$c4]\n\
c8            [$c2,$c4]\n\
c9            [$c5,$c6]\n\
c10           [$(cO[CX4]),$(c[NH]C=O),$(cN([CX4])C=O)]\n\
C2EW3         c[$EW3]\n\
c11           [c;!$C2EW3;$c3]\n\
c12           [$c11]1[$c11][$c11][$c11][$c11][$c11]1\n\
c13           [$c5,$c12]\n\
n1            [$([nH]),$([nX3][CX4])]\n\
#\n\
#  \n\
#  Definitions for orienting benzimidazole/benzotriazole N-H\n\
#\n\
Don           [$(c[N;H,H2]),$([nH])]\n\
Acc           [$([nX2]),$(a=[O,S;X1]),$([c;$R2][nX2])]\n\
NoHB          [a;!$Don;!$Acc]\n\
#\n\
#  Atom type to prevent deprotonation of more than one hydroxyl\n\
#  in aromatic, acidic OH \n\
XOHNeu        [a,A;!$(a[O-])]\n\
#        \n\
#---------------------------------------------------------------\n\
# Aliphatic amines\n\
#\n\
CtoHet        C[O,F,Cl,Br,I,$(C(F)(F)F),$(C#N)]\n\
Csp3          [C;X4;!$CtoHet]\n\
Prim          [N;H2;X3][$Csp3]\n\
Sec           [N;H;X3]([$Csp3])[$Csp3]\n\
Ter           [NX3]([$Csp3])([$Csp3])[$Csp3]\n\
AlipAmin      [$Prim,$Sec,$Ter]         \n\
#\n\
# \n\
# Aliphatic amine nitrogens linked by ethylene spacer(s)\n\
# require special treatment:\n\
# H2N-CH2-CH2-NH2    pKa:  10/7\n\
# Me2N-CH2-CH2-NMe2  pKa:   9/6\n\
# Piperazine         pKa:  10/5\n\
#\n\
# We adopt tactic of allowing mono and dications\n\
# when the amine nitrogens are linked acyclically but \n\
# only monocation when the nitrogens are in a ring.  The\n\
# substructural gymnastics with $NTriAm prevent disaster\n\
# in unlikely event of fused piperazines sharing nitrogen\n\
#\n\
N1Cat         NC[A,a;+]\n\
N2Cat         NCC[A,a;+]\n\
N2Cat2        N(CC[A,a;+])CC[A,a;+]\n\
N2CatCy       [N;$R][C;$R][C;$R][A,a;+]\n\
N2CatAcy      [$N2Cat;!$N2CatCy]\n\
NTriAm        [$AlipAmin](CC[$AlipAmin])CC[$AlipAmin]\n\
DABCOn        [$AlipAmin;!$NTriAm]1(C2)CC[N;X4;+;H](C2)CC1\n\
Piperazn      [$AlipAmin;!$NTriAm;!$DABCOn]1CC[N;X4;+;H,H2]CC1\n\
CycAm2n       [$AlipAmin;!$NTriAm;!$DABCOn;!$Piperazn]\n\
#\n\
# Aliphatic amines with pKa close to 7 should be represented \n\
# as both neutral and charged forms.  It is easiest to protonate \n\
# first (along with the other aliphatic amines) and enumerate\n\
# using protonated forms as starting points\n\
#\n\
Morph         [N;H,H2;+;X4]1CCOCC1\n\
Piperaz1      [N;+;X4;H,H2]1CCN([$(C=O),$(S(=O)=O)])CC1\n\
Piperaz2      [N;H;+;X4]1(Ca)CCNCC1\n\
Piperid       [N;+;X4;H,H2]1CCC(F)CC1\n\
PipOxa        [N;+;X4;H,H2]1CC[$(C=O),$(S=O)]CC1\n\
Aminpka7      [$Morph,$Piperaz1,$Piperaz2,$Piperid,$PipOxa]\n\
#---------------------------------------------------------------\n\
#  \n\
#  Amidines & guanidines:  \n\
#\n\
g1a          [$([CX4]),$(c1ccccc1),$(c1sccc1),$(c1cscc1)]\n\
g1b          [$(c1ncccc1),$(c1cnccc1),$(c1ccncc1)]\n\
g1c          C(=[$im,$nph])[$am,$nhph,$nrph]\n\
g1           [$g1a,$g1b,$g1c]\n\
g2a          [$(C#N),$(N(=O)=O),$(S(=O)=O),$(C~[N;+])]\n\
g2b          [$(c1naao1),$(c1onaa1),$(a1nnaa1),$(a1anna1)]\n\
g2           [$g2a,$g2b]\n\
g3           [$([c;!$g1;!$g2]),$(C=O)]\n\
#\n\
GuanPrt0     [$im]=C([$am])[$am,c,C&X4]\n\
GuanPrt1     [NX2](-[$g1])=C([$am])[$am,c,C&X4]\n\
GuanPrt2     [$im]=C([$am,c,C&X4])[$([NX3][CX4]),$([N;X3;H])][$g1] \n\
GuanPrt3     [NX2](-[$g3])=C([$am])[$am]\n\
GuanPrt4     [$im]=C([$am])[$([NX3][CX4]),$([N;X3;H])][$g3]\n\
FamdPrt0     [$im]=[CH]([$am])\n\
FamdPrt1     [NX2](-[$g1])=[CH][$am]\n\
FamdPrt2     [$im]=[CH][$([NX3][CX4]),$([N;X3;H])][$g1] \n\
FamdPrt3     [NX2](-[$g3])=[CH][$am]\n\
FamdPrt4     [$im]=[CH][$([NX3][CX4]),$([N;X3;H])][$g3]\n\
#\n\
#---------------------------------------------------------------\n\
#\n\
#  Heteroaromatic nitrogen\n\
#\n\
#  Typically 2-connected (pyridine-like rather than pyrrole-like) \n\
#  heteroaromatic nitrogen is best represented in its neutral from \n\
#  at physiological pH. However there are some notable exceptions \n\
#  to this rule which fall into two groups according to whether\n\
#  the nitrogen is strongly or moderately basic. \n\
# \n\
#  The strongly basic group is typified by 4-aminopyridine and\n\
#  its ring-fused analogues.  \n\
#\n\
AmPyrid4a     [nX2]1[$c12,$c5][$c12,$c5][$cam][$c12,$c5][$c12,$c5]1 \n\
AmPyrid4b     [n;X2;!$AmPyrid4a]1[$c3][$c3][$cam][$c3][$c3]1 \n\
#\n\
#  A number of heteroatomic nitrogen types are expected to have\n\
#  pKa close to neutral pH\n\
#\n\
#     2-Aminopyridine & analogs:  Note restriction of C4 to force\n\
#                                 correct behaviour for isoquinolines\n\
#\n\
AmPyrid2a     [nX2]1[$cam][$c12,$c5][$c12,$c5][$c5][$c5]1\n\
AmPyrid2b     [nX2]1[$cam][$c5][$c5][$c12,$c5][$c12,$c5]1\n\
AmPyrid2c     [nX2]1[$cam][$c12][$c12][$c12][$c12]1\n\
AmPyrid2      [$AmPyrid2a,$AmPyrid2b,$AmPyrid2c]\n\
#\n\
#     Alkoxy, amido & anilino substituents in 4 position \n\
#     push pyridine pKa into interesting range\n\
#\n\
ROa           [$(O[CX4]),$([N;H;X3]C=O),$([N;X3]([CX4])C=O)]\n\
ROb           [$([N;H;X3]c1ccccc1),$([N;X3]([CX4])c1ccccc1)]\n\
RO            [$ROa,$ROb]\n\
RO4Pyrid      [nX2]1[$c12,$c5][$c12,$c5]c([$RO])[$c12,$c5][$c12,$c5]1\n\
#     \n\
#     Pyridines to be enumerated\n\
#\n\
PyridEnum    [$AmPyrid2,$RO4Pyrid,$AmPyrid4b]\n\
#     \n\
#     2,4-Diaminopyrimidine\n\
#\n\
Am2Pyrim     [nX2]1[$cam][nX2][$cam][$c5,$c12][$c5,$c12]1\n\
#\n\
#     4-Aminopyridazine \n\
#\n\
AmPyridaz4   [nX2]1[nX2][$c1][$cam][$c5,$c12][$c5,$c12]1\n\
#\n\
#     6-Amino-isoquinoline\n\
#\n\
AmIsoQuin6   [nX2]1[$c1][$c1]c2[$c1]c([$am])[$c1][$c1]c2[$c1]1\n\
#\n\
Rng6Enum     [$PyridEnum,$Am2Pyrim,$AmPyridaz4,$AmIsoQuin6]   \n\
#\n\
#     Imidazole & benzimidazole\n\
Imidaz       [nX2]1[$c1][$n1][$c1][$c1]1\n\
BzImidaz     [nX2]1c([$am])[$n1][$c2][$c2]1\n\
Imdz         [$Imidaz,$BzImidaz]\n\
#\n\
#     Diazaindenes\n\
#\n\
DiazInd1     [nX2]1[$c1][$c1][$c1]c2[$n1][$c1][$c1]c12\n\
DiazInd2     [nX2]1[$c1][$c1]c2[$n1][$c1][$c1]c2[$c1]1\n\
DiazInd3     [nX2]1[$c1]c2[$n1][$c1][$c1]c2[$c1][$c1]1\n\
DiazInd4     [nX2]1[$c1][$c1]n2c1[$c1][$c1][$c1][$c1]2\n\
DiazInd5     [nX2]1[$c1][$c1]c2[$c1]n([CX4])[$c1]c2[$c1]1\n\
DiazInden    [$DiazInd1,$DiazInd2,$DiazInd3,$DiazInd4,$DiazInd5]\n\
#\n\
#\n\
#     Triazaindenes [Thanks to Loredana for flagging these up]\n\
#\n\
TriazInd1    [nX2]1[$c5]c2[nX2][$c5][nX3]c2[$c13][$c13]1\n\
TriazInd2    [nX2]1[$c5]c2[$c5][nX2][nX3]c2[$c13][$c13]1\n\
TriazInden   [$TriazInd1,$TriazInd2]\n\
#     \n\
# hetarmpka7   [$Rng6Enum,$Imdz,$DiazInden,$TestT]   \n\
#--------------------------------------------------------------\n\
#\n\
#  Ionisable sulfonamides are divided into two classes according \n\
#  to whether the deprotonation should be enumerated or not.  These rules \n\
#  are hellishly difficult to get right but at least enumeration will\n\
#  make sure that both forms will be present when we're less sure\n\
#\n\
SO2Grp     [$([F,Cl,Br]),$(N(=O)=O),$(C#N),$(C(F)(F)F),$([C,S](=O)[c,C])]\n\
SO2R1a     [$(C=O),$(S(=O)=O),$(C#N),$(N(=O)=O)]\n\
SO2R1b     [$(c1n[o,s]aa1),$(c1[o,s]naa1),$(c1nanan1)]\n\
SO2R1c     [$(c1nncn1),$(c1nnc[o,s]1)]\n\
SO2R2a     [$(c1naccc1),$(c1cancc1),$(c1ncncc1),$(c1ncccn1)]\n\
SO2R2b     [$(c1ncc[o,s]1),$(c1cnc[o,s]1),$(c1c[o,s]cn1)]\n\
SO2R2c     [$(c1cc([$SO2Grp])ccc1),$(c1ccc([$SO2Grp])cc1)]\n\
Sulfam1    [NH]([$SO2R1a,$SO2R1b,$SO2R1c])S(=O)=O\n\
Sulfam2    [NH]([$SO2R2a,$SO2R2b,$SO2R2c])S(=O)=O\n\
#\n\
#  Acidity of sulfonamides can be increased by linking an electron\n\
#  withdrawing group to directly to sulfur atom of sulfonamide.  These\n\
#  types tend to be rare but are of great interest as phosphate mimics.\n\
#  Typically the pKa will be close to 7 so these types are set up for \n\
#  enumeration.\n\
#\n\
SulfamSa   [$(C(F)F),$SO2R1b,$SO2R1c]\n\
SulfamSb   [$(c1[o,s]ccn1),$(c1ncncc1),$(c1ncccn1)]\n\
Sulfam3    [N;H,H2]S(=O)(=O)[$SulfamSa,$SulfamSb] \n\
#\n\
#-----------------------------------------------------------------\n\
#\n\
#  Sulfonyl triazoles are pretty obscure but since we bought some\n\
#  as phosphate mimics we should make the effort to deprotonate them\n\
#  in an appropriate manner for pKa 5.2-6.2\n\
#\n\
SO2trz1    [nH]1c(S(=O)=O)c[nX2][nX2]1\n\
SO2trz2    [nH]1[nX2]c(S(=O)=O)c[nX2]1\n\
SO2trz3    [nH]1[nX2][nX2]c(S(=O)=O)c1\n\
SO2trz4    [nH]1[nX2]c(S(=O)=O)[nX2]c1\n\
SO2trz5    [nH]1c(S(=O)=O)[nX2]c[nX2]1\n\
SO2trz     [$SO2trz1,$SO2trz2,$SO2trz3,$SO2trz4,$SO2trz5]\n\
#\n\
#-----------------------------------------------------------------\n\
#\n\
#  Phenols with selected electron withdrawing substituents in \n\
#  the right places are identified for enumeration.  Note that\n\
#  we've not worked too hard to check what other substituents\n\
#  are that might push the pKa back up.\n\
#\n\
PhOH2a    [OH]c1c([$(N(=O)=O),$(C#N),$(C(=O)[N;H,H2])])cccc1\n\
PhOH2b    [OH]c1c([$([C;$r5](=O)OC),F,Br,Cl])cccc1\n\
PhOH3     [OH]c1cc(N(=O)=O)ccc1  \n\
PhOH4     [OH]c1ccc([$(N(=O)=O),$(C#N),$(C(=O)[c,C]),$(S(=O)(=O)[c,C])])cc1\n\
PhOHenum  [$PhOH2a,$PhOH2b,$PhOH3,$PhOH4]\n\
#\n\
#-------------------------------------------------------------------";

}

#endif // TAUT_ENUM_PROTONATE_VB
